Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2):136-49

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  BONE METASTASES IN THE ERA OF TARGETED TREATMENTS 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 June;63(2):136-49

DOI: 10.23736/S1824-4785.19.03206-0

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Molecular imaging of bone metastases using tumor-targeted tracers

Najme KARAMZADE-ZIARATI 1, Reyhaneh MANAFI-FARID 1, Bahar ATAEINIA 2, Werner LANGSTEGER 3, Christian PIRICH 4, Felix M. MOTTAGHY 5, 6, Mohsen BEHESHTI 4, 5

1 Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran; 2 Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; 3 PET-CT Center Linz, Department of Nuclear Medicine, Ordensklinikum, St. Vincent’s Hospital, Linz, Austria; 4 Department of Nuclear Medicine & Endocrinology, Paracelsus Medical University, Salzburg, Austria; 5 Department of Nuclear Medicine, University Hospital, RWTH University, Aachen, Germany; 6 Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands



Bone metastasis is a disastrous manifestation of most malignancies, especially in breast, prostate and lung cancers. Since asymptomatic bone metastases are not uncommon, early detection, precise assessment, and localization of them are very important. Various imaging modalities have been employed in the setting of diagnosis of bone metastasis, from plain radiography and bone scintigraphy to SPECT, SPECT/CT, PET/CT, MRI. However, each modality showed its own limitation providing accurate diagnostic performance. In this regard, various tumor-targeted radiotracers have been introduced for molecular imaging of bone metastases using modern hybrid modalities. In this article we review the strength of different cancer-specific radiopharmaceuticals in the detection of bone metastases. As shown in the literature, among various tumor-targeted tracers, 68Ga DOTA-conjugated-peptides, 68Ga PSMA, 18F DOPA, 18F galacto-RGD integrin, 18F FDG, 11C/18F acetate, 11C/18F choline, 111In octreotide, 123/131I MIBG, 99mTc MIBI, and 201Tl have acceptable capabilities in detecting bone metastases depending on the cancer type. However, different study designs and gold standards among reviewed articles should be taken into consideration.


KEY WORDS: Bone; Neoplasm metastasis; Molecular imaging

top of page